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Lectins are the proteins widely distributed in nature 
and isolated from animal and human tissues as well as 
from plants, viruses and bacteria. The characteristic 
feature of these biopolymers consists in their ability to 
recognize specifically and bind reversibly to glycoside 
structures in the complexes that contain carbohydrates. 
Lectins are highly stable and multifunctional molecules 
and may be isolated from various sources as well as 
produced by recombinant technology. It is important 
also that their reactions with soluble compounds and 
cells may be reversible in the presence of simple sugars.
The majority of lectins studied up to date possesses 
hemagglutinating activity, and some of them cause 
agglutination of malignant, embryonic cells, yeast 
and bacteria [1], and demonstrate antitumor activity 
and immunomodulating effects [2–4]. For example, 
the mitogenic effect of lectins toward T-lymphocytes, 
their ability to stimulate the production of various cy-
tokines, in particular TNF-α, IFN-γ, IFN-α, proinflam-
matory interleukins (IL-1α, IL-1β, IL-6, IL-12), have 
been revealed. There are some reports on stimulating 
effects of lectins on macrophages and granulocytes [5, 
6]. Such biologic properties of lectins are considered 
as potentially important ones for the therapy of various 
pathologies related to immune system disorders and 
cancer.
Immunomodulating effects of lectins [7, 8] may be 
promising in cancer treatment, in particular for the pre-
vention of metastasizing after the surgical removal of 
tumor. Therefore, the cytotoxic lectins as unique im-
munomodulators with targeted action [9–11] are ad-
vantageous for the development of novel preparations 
for vector therapy of malignant tumors. The complex of 
means for elevation of immunoreactivity in combina-
tion with immunotherapy may significantly elevate an 
efficacy of treatment and improve the quality of life of 
cancer patients.
It is known that anticancer action of many lectins 
of plant and fungal origin is realized via their immuno-
modulating properties. Recently, the study of the lec-
tins of bacterial origin has been initiated. In this regard, 
of special interest is the group of extracellular lectins 
of saprophytic bacteria from genus Bacillus with a rare 
specificity toward acidic carbohydrates, in particular 
glucuronic, N-acetyl- and N-glycolylneuraminic acids, 
fructose-1,6-diphosphate [12], which is unusual for 
lectins of plant and animal origin.
We have earlier shown that the binding of cytotoxic 
lectins (CL) from B.subtilis B-7025 to cell surface recep-
tors modifies tumor-associated antigens elevating their 
immunogenicity, which may be advantageous for the de-
velopment and generation of anticancer vaccines [13, 14]. 
However, antitumor and immunomodulating properties CL 
from B.subtilis B-7025 in itself, have not been yet studied.
An established preventive anticancer effect of CL 
from B.subtilis B-7025 in experimental tumors of different 
genesis [15] has forced us to study immunomodulating 
properties of the preparation using experimental tumor 
models. The present work was aimed at studying pre-
ventive antitumor affect of CL from B.subtilis B-7025 on 
the tumor growth and nonspecific immunity in sarco-
ma-37 transplanted mice.
MATERIALS AND METHODS
The cytotoxic lectins were isolated from cultural 
fluid of B. subtilis strain B-7025 registered in the col-
lection of Institute of Microbiology and Virology NAS 
of Ukraine [16] by the method developed by us ear-
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lier [12]. Isolated and purified cytotoxic lectins are 
thermostable glycoproteins with isoelectric points of 
3.6 and 4.4 units possessing molecular mass poly-
morphism caused by formation of multiple forms of 
the biopolymer [17].
2-2.5-months old female Balb/c mice were used in 
the study. The animals were injected subcutaneously 
with CL (0.2 mg per animal) 4 times with 1–2 days in-
tervals. The next day after the last CL administration, 
0.5 x 106 sarcoma 37 cells were grafted in the thigh 
muscle of both experimental and control animals. For 
prophylactic schedule of treatment with CL, animals 
were housed in 2 groups: mice from 1st group were 
further treated with CL (0.05 mg per animal) twice 
a week for 3 weeks (combined scheme), while mice 
from 2nd experimental group (prophylactic scheme) 
and control animals received physiologic solution. 
Using a caliper, the tumor diameters were measured 
daily, and tumor volumes were calculated using the 
following formula: V = D × d2 × 0.52 (V, tumor volume; 
D, the largest dimension; d, the smallest dimension).
All experiments were approved by Ethical Committee 
of the institute.
The functional activity of the effectors of immuno-
logic response was studied in experimental animals 
one day prior to tumor transplantation and on days 
6 and 34 after tumor cell transplantation (TCT) (as well 
as in control animals).
The functional activity of peritoneal macrophages 
(PMp) was evaluated by the level of oxygen-dependent 
metabolism and cytotoxicity. Oxygen-dependent 
metabolism was determined by reduction of tet-
razolium nitroblue (NBT) [18]. Optical density of 
reduced NBT was analyzed using microplate photom-
eter “Reader”(Labotech, Latvia) at the wavelength of 
630 nm.
The cytotoxic activity of PMp was evaluated by MTT 
colorimetric test [19, 20]. The cells of allogenic tumor 
served as target cells. Optical density was measured 
using microplate photometer “Reader” (Labotech, 
Latvia) at the wavelength of 545 nm. Specific killing 
of target cells was calculated by formula:
CA = (1 – (Em – Ee)/(Et – Ec)) × 100%, where E is 
mean absorbance of the wells: Em — the wells with 
mixture of the target and effector cells; Ee — the wells 
with the effector cells; Et — the wells with the target 
cells; Ec — control of medium [20].
The cytotoxic activity of spleen mononuclear cells 
was evaluated by MTT colorimetric test [20, 21]. Mono-
nuclear cells were isolated by standard method from 
spleen by centrifugation of cell suspension (obtained 
after homogenisation of spleen tissue in Potter’s ho-
mogenizer) in the Ficoll-verografin density gradient 
(ρ = 1.077). Cell suspensions with viability higher then 
80% were used [22]. K562 cells were used as target 
cells, sensitive to natural killer cells (NK). The ratio be-
tween effector cells and target cells was 1/50; duration 
of co-incubation was 18 h. Then, 20 μl of MTT solution 
(5 mg/ml MTT in PBS) were added to each well and the 
plates were incubated for 4 h at 37 ˚C. In order to stop 
the reaction, 100 μl DMSO were then added with vig-
orous mixing. Optical density of incubation mixture in 
the wells was measured using microplate  photometer 
“Reader” (Labotech, Latvia) at the wavelength of 
545 nm. Cytotoxic activity of spleen mononuclear cells 
was calculated by the foresaid formula.
Anticancer efficacy of lectin was evaluated by ana-
lysis of tumor growth dynamics and average life span 
(ALS) of experimental animals using tumor growth in-
hibition index (TGI) and ALS modulation index (MI) [23, 
24]. The indices were calculated using the formulas:
TGI = ((V – Vk)/Vk) × 100%, where V is mean tumor 
volume calculated for experimental groups treated by 
CL; Vk is mean tumor volume in the control group [23].
MI = ((E – K)/K) × 100%, where E is mean ALS 
of groups treated by CL; K is mean ALS in control 
group [24].
Statistical analysis of the data was performed by 
standard methods using Student’s t-test.
RESULTS AND DISCUSSION
The inhibition of sarcoma 37 growth was assessed 
in the animals treated with CL isolated from meta-
bolic products of В. subtilis В-7025 in prophylactic or 
combined schedule. As seen in Fig. 1, such treatment 
resulted in tumor growth inhibition. On day 28 after 
tumor cell transplantation (TCT), TGI in mice from 
experimental group I was 66%, while in mice preven-
tively treated with lectin (experimental group II) TGI 
amounted to 50.5%. The average life span (ALS) of 
experimental animals relative to untreated controls 
increased (Table).
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Fig. 1. Effect of prophylactic and combined use of lectin on the 
growth of sarcoma 37 in tumor bearing mice. 1 — administration 
of CL before and after tumor cell transplantation, 2 — administra-
tion of CL before tumor cell transplantation, 3 — control
Table. Average life span of mice with transplanted sarcoma 37 upon pro-
phylactic and combined treatment with bacterial lectin
Group Number of mice
Dosage and method 
of administration of lectin, 
mg/animal
ALS, M ± m t MI,%
CL→TCT→CL 8 0.2 before and 0.05 after 
TCT, s/c
85.1 ± 9.3* 3.6 69.5
CL→TCT→PS 7 0.2, s/c 71.1 ± 4.5* 4.1 41.6
Control 8 - 50.2 ± 2.3 - -
Notes: *— p < 0.05 compared to control group.
The effects of CL on tumor growth in mice may be 
caused by two reasons: activation of antitumor defense 
and direct cytotoxic action of lectin on tumor cells. We 
have attempted to analyze CL effects on the activity of 
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PMp in tumor-bearing animals. Macrophages repre-
sent an important component of antitumor resistance. 
According to the literature data [25, 26], the lectins of 
different origin activate both peripheral blood mono-
cytes and resident macrophages. In our experiment 
four injections of bacterial lectins to intact animals at a 
dose of 0.2 mg have led to activation of these effector 
cells. Sarcoma 37 transplantation additionally stimu-
lated their activity registered on day 6 after TCT. This 
trend persists even on day 34 after TCT in the case of 
the combined schedule of the treatment, although the 
differences were not significant (data are not shown).
On day 6 after tumor transplantation, in both ex-
perimental groups the index of cytotoxic activity of 
PMp increased more than twice compared to that in 
tumor-bearing control (Fig. 2). On day 34, cytotoxicity 
of macrophages was similar to control values. These 
results allow us to suppose that at the late stages of 
tumor growth macrophages-suppressors that inhibit 
macrophage-mediated cytotoxicity and promote tu-
mor growth, began to be involved in the process.
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Fig. 2. Effect of prophylactic and combined use of lectin on 
cytotoxic activity of peritoneal macrophages from mice bear-
ing sarcoma 37. І — administration of CL before and after TCT, 
ІІ — administration of CL before TCT, ІІІ — tumor-bearing control
It is known that the development of tumor growth 
suppresses the functional activity of splenocytes, includ-
ing natural killer cells. As one may see in Fig. 3, in tumor-
bearing mice an immunosuppressive effect of tumor 
toward these effector cells of natural immunity could be 
observed manifesting by the decreased ability of spleen 
mononuclear cells from control animals to cause lysis of 
target cells.
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Fig. 3. Effect of prophylactic and combined use of lectin on 
cytotoxic activity of mononuclear splenocytes from mice bear-
ing sarcoma 37. І — administration of CL before and after TCT, 
ІІ — administration of CL before TCT, ІІІ — tumor bearing control, 
IV — intact control
In prophylactic use of lectin, on day 6 after TCT 
elevated cytotoxicity of splenocytes against sensitive 
К562 cells was evident. However, the most potent stimu-
lating effect of prophylactic and combined use of lectin 
on cytotoxic activity of spleen cells was revealed on day 
34 after TCT: the cytotoxicity of macrophages of experi-
mental animals was more than twice higher than those 
of control tumor-bearing animals. Since NK-sensitive 
K562 cells were used as target cells, we suppose that NK 
cells were predominantly responsible for the observed 
cytotoxic effect of spleen mononuclear cells. Neverthe-
less, other subpopulations of spleen lymphoid cells can 
also be responsible for negligible part of cytotoxic effect 
of spleen cells against target cells used in the study.
Therefore, antitumor effect of lectin administration is 
accompanied by activation of immunologic reactivity of 
mice. Stimulating influence of lectins on tumor-bearing 
animals at the early stage of tumor growth has been reg-
istered for functional activity of peritoneal macrophages, 
and at the late stage — for spleen mononuclear cells.
In oncological practice bacterial lectins are used as 
the components of antitumor vaccines and as adjuvants 
but not as an individual anticancer or immunomodulating 
preparations. Nevertheless, high cytotoxicity against ma-
lignant cells has been already shown for several lectins 
of plant and fungal origin [3–5, 27, 28]. Antiproliferative 
activity of lectins is often combined with their ability to 
stimulate distinct reactions of immune system [2, 3, 
6–8, 26]. It has been previously shown that В. subtilis 
B-7025 lectins are highly cytotoxic in vitro against tumor 
cells of different genesis [17]. We also have described 
[15] significant inhibitory preventive influence of lectins 
from В. subtilis B-7025 in vivo on tumor growth and 
metastasizing in mice. This antitumor effect of bacterial 
lectin is very similar to that revealed for Aloe vera lectin 
[29] and mistletoe lectins [5].
In present work immunomodulating properties of 
cytotoxic lectin in sarcoma 37 bearing mice in dynamics 
were displayed. This allows us to assume that antitumor 
effect of CLs like some other lectins is realized via not 
only its cytotoxic action against tumor cells but also via 
enhancing impact on innate immunity. According to our 
data, the combined schedule of В. subtilis lectins admin-
istration seems to be more effective than prophylactic one 
to provide complete realization of all beneficial potentials 
of lectins.
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